Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.28 USD
-0.02 (-1.54%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.29 +0.01 (0.78%) 7:40 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 101 - 120 ( 277 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Cohort 1 Data Establishes Safety, Hints at Efficacy for CLS-AX/ wAMD; Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Impressive Early Safety and Efficacy for CLS-AX in Wet AMD-Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Virtual Marketing by Analyst Zegbeh Jallah Begins @ 12pm ET Tomorrow
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
XIPERE-PDUFA Set for October 30; CLS-AX Initial Safety Results in Mid:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
FDA Accepts XIPERE''s NDA, CLS-AX''s Phase 1 Data Up Next #2021TopPicks
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: June 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- Raising PT to $9 Based on XIPERE''s NDA & Key Catalysts Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q1: First-Look at CLS-AX Safety Data Mid:21; XIPERE PDUFA by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
NDA for XIPERE Resubmitted, PDUFA Likely by YE2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
NDA Resubmitted; We Anticipate U.S. Approval by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Striking the Right Synergy with CLS-AX SCS Delivery; OASIS Safety Data Mid:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from wAMD Key Opinion Leader Call: Treat and Extend; Once and Done
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L